Tvardi Therapeutics, Inc. SEC filings TVRD
Tvardi Therapeutics, Inc. has 809 filings in SEC EDGAR's recent list, going back to Dec 6, 2005. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 13, 2026 | — |
| EFFECT | Filing | May 12, 2026 | — |
| CORRESP | Letter to the SEC | May 8, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| POS EX | Filing | Apr 1, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2025 | — |
| 425 | Filing | Mar 24, 2025 | — |
| SEC STAFF LETTER | Filing | Feb 14, 2025 | — |
| EFFECT | Filing | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Jan 24, 2025 | — |
| 425 | Filing | Jan 21, 2025 | — |
| 425 | Filing | Jan 17, 2025 | — |
| SEC STAFF LETTER | Filing | Jan 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2025 | — |
| 425 | Filing | Dec 30, 2024 | — |
| 425 | Filing | Dec 20, 2024 | — |
| 425 | Filing | Dec 18, 2024 | — |
| EFFECT | Filing | May 11, 2022 | — |
| CORRESP | Letter to the SEC | May 9, 2022 | — |
| CORRESP | Letter to the SEC | Apr 26, 2022 | — |
| CORRESP | Letter to the SEC | Apr 22, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2022 | — |
| SEC STAFF LETTER | Filing | Feb 18, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 5, 2020 | — |
| EFFECT | Filing | Apr 4, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2019 | — |
| CT ORDER | Filing | Mar 21, 2019 | — |
| CT ORDER | Filing | Sep 11, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2017 | — |
| CORRESP | Letter to the SEC | Sep 20, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2017 | — |
| EFFECT | Filing | Mar 24, 2017 | — |
| CORRESP | Letter to the SEC | Mar 23, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2017 | — |
| EFFECT | Filing | May 13, 2015 | — |
| CORRESP | Letter to the SEC | May 13, 2015 | — |
| CORRESP | Letter to the SEC | May 13, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2015 | — |
| D | Filing | Dec 11, 2014 | — |
| CT ORDER | Filing | Feb 3, 2014 | — |
| CERTNAS | Auto-generated paper document | Jan 30, 2014 | — |
| EFFECT | Filing | Jan 30, 2014 | — |
| CORRESP | Letter to the SEC | Jan 28, 2014 | — |
| CORRESP | Letter to the SEC | Jan 28, 2014 | — |
| 8-A12B | Filing | Jan 27, 2014 | — |
| CORRESP | Letter to the SEC | Dec 30, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2013 | — |
| CORRESP | Letter to the SEC | Nov 8, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2013 | — |
| DRS | Filing | Oct 4, 2013 | — |
| D | Filing | Jul 21, 2010 | — |
| REGDEX/A | Auto-generated paper document | Aug 1, 2008 | — |
| REGDEX | Auto-generated paper document | Jul 16, 2008 | — |
| REGDEX | Auto-generated paper document | Dec 12, 2006 | — |
| REGDEX/A | Auto-generated paper document | Jan 19, 2006 | — |
| REGDEX | Auto-generated paper document | Dec 6, 2005 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sugar Land, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1346830
- Former names
- Cara Therapeutics, Inc. (until Apr 11, 2025); Cara Therapeutics Inc (until Jul 21, 2010)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.